The White House has scheduled two new meetings tied to the FDA’s cannabidiol (CBD) enforcement policy, adding to the five stakeholder discussions that already occurred earlier this month.

According to the Office of Information and Regulatory Affairs calendar, Groff North America Inc., a company involved in hemp genetics and botanical operations, is scheduled to meet with officials on April 16 at 3:30 p.m. The meeting request lists Thomas Leverte, the company’s CEO, as the requester’s representative. A second meeting is set for April 17 at 1:30 p.m. with My TCBD Inc., a Michigan-based hemp and CBD company founded by Kelly Young, who is also listed as the requester’s representative.

Both meetings are connected to the FDA document titled Cannabidiol (CBD) Products Compliance and Enforcement Policy, which remains under White House review at the notice stage.

The newly added sessions come after five earlier meetings tied to the same policy were scheduled for April 1, April 2 and April 7. Those discussions involved David Heldreth of Panacea Plant Sciences, Trent Woloveck of Jushi Holdings, Mackie Barch of Story Cannabis, Iowa hemp farmer Earl Ramey, and OCan Group, LLC. With the addition of the April 16 and April 17 meetings, the total number of scheduled stakeholder sessions tied to the policy has now risen to seven.

The continuing stream of meetings indicates that interest in the pending CBD guidance remains strong across the broader hemp and marijuana industries. Although the FDA has not yet released the policy publicly, its title suggests it will lay out how federal regulators plan to approach compliance and enforcement for CBD products.

The ongoing review comes as federal officials face mounting pressure to provide clearer rules for hemp-derived cannabinoids, an issue that has taken on added urgency as broader cannabis policy changes continue to unfold in Washington.